A recent update from the Washington University of Medicine in St. Louis brings more evidence that the highly dangerous coronavirus variants will adversely affect medical treatments and evade vaccines against them.
Another Study Proves Weaken Response Towards COVID Strains
The study found that if the patient is infected with any of the variants, his immune response will not be as effective as it could be expected after he receives any of the three vaccines that have been administered widely across the country.
The assessment was conducted on the strains of the coronavirus which were detected in the United Kingdom, South Africa, and Brazil. The antibodies created in the body can perfectly defense the original version of the novel coronavirus. However, with the presence of these three highly contagious and stronger variants, these antibodies will not be sufficient to fight against them.
Since this becomes another indication that the effectiveness of the vaccines and antibody-based medications will be reduced. Besides these variants bring a threat to be dominant throughout the country within the coming few months.
The main part of the study was the testing of antibodies collected from the blood samples of people who had received the shots of the Pfizer vaccine against COVID-19 as well those who recovered after they were contracted with the coronavirus.
Earlier, the scientists had developed a special experimental vaccine against COVID-19 in the university, which can be given through the nose. The researchers also used this vaccine among monkeys, hamsters, and mice, and they also treated the antibodies of these animals.
After conducting all the experiments and assessments, the researchers concluded that the variants will only be neutralized if there is the presence of much higher levels of antibodies.
The senior author of the study, Dr. Michael Diamond, a professor of medicine and molecular microbiology as well as pathology and immunology, said that their concern was the expected protective level of antibodies in people who recovered from an infection of COVID-19 and those who got vaccinated against it. However, this level of antibodies might not be enough to give protection against these new variants.
In a university news release, he explained that in people there is a wide variation in the quantity of producing these antibodies from person to person as part of the response to natural infection or vaccination. When some people respond with production at a very high level, they are likely to act against the new worrisome variants. Whereas in some others, including those who have low immunity power as that of an elderly adult, such a high level of production of antibodies will not occur.
Dr. Diamond added that as their data indicates if the level of antibodies needed for protection against the variants rises tenfold, they might not have enough. Those who least likely to have it are those who need it at the most.
He also indicated that the consequences of the new variants are yet to be found out.
In a further explanation, Dr. Diamond said that the measures of protection are not only reliable to antibodies. There are certain other elements too in the immune system that would compensate for the higher resistance of the antibodies, and on his, further research will be conducted soon.